AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2690-1919/599
12nd Medical Department, Hematology and Oncology, Klinik Donaustadt, 1220 Vienna, Austria.
2Danube Science, 1220 Vienna, Austria.
3Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Austria.
4Medical Clinic, Hematology and Oncology, See-Spital Horgen, 8810 Horgen, Switzerland.
*Corresponding Author: Christian Sebesta, 2nd Medical Department, Hematology and Oncology, Klinik Donaustadt, 1220 Vienna, Austria.
Citation: Christian Sebesta, Helena Bozic, Christian G Sebesta, Marie Christine Sebesta, Boris Bozic, (2026), Novel and Personalized Therapy for monoclonal gammopathy of renal significance, J Clinical Research and Reports, 23(2); DOI:10.31579/2690-1919/599
Copyright: © 2026, Christian Sebesta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 03 November 2025 | Accepted: 11 November 2025 | Published: 09 January 2026
Keywords: monoclonal gammopathy of renal significance; renal biopsy; bortezomib; pomalidomide; daratumumab; isatuximab; monoclonal antibodies targeting bcma; venetoclax; chimeric antigen receptor (car) t-cells
Monoclonal gammopathy of renal significance (MGRS) refers to renal diseases caused by a monoclonal protein (M protein) secreted by a small plasma cell clone or other B-cell clones in patients who do not meet the diagnostic criteria for multiple myeloma or other B-cell malignancies. MGRS results from the deposition of composite monoclonal immunoglobulin (Ig) and light or heavy chain (LC or HC) fragments of varying sizes produced by plasma cells or plasmoblasts that proliferate clonally, possibly under the influence of T-helper lymphocytes. The diagnosis of MGRS involves four steps: (1) identifying the underlying monoclonal protein in serum and urine, (2) determining the clonal B-cell population responsible for secreting the monoclonal protein, (3) assessing any extrarenal manifestations of the clonal B-cell population, and (4) performing a renal biopsy to identify the pattern of renal parenchymal damage and detect monoclonal protein. Treatment for MGRS is based on targeting the causative B-cell clone. The goal of treatment is to preserve or improve organ function by targeting the B-cell or plasma cell clone responsible for M-protein production and organ damage. Several substances are available for treatment, including proven options such as bortezomib, cyclophosphamide, and pomalidomide, as well as newly developed substances like CD38 antibodies (daratumumab, isatuximab), monoclonal antibodies targeting BCMA, BCL-2 inhibitors (venetoclax), and chimeric antigen receptor (CAR) T-cells.
Monoclonal gammopathy of renal significance (MGRS) encompasses all kidney diseases caused by a nephrotoxic monoclonal immunoglobulin (M-protein) produced by a small, often indolent plasma cell or B-cell clone in patients who do not fulfill the diagnostic criteria for overt multiple myeloma (MM), Waldenström’s macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), or lymphoma [1]. According to the updated consensus of the International Kidney and Monoclonal Gammopathy Research Group (IKMG), MGRS includes not only monoclonal gammopathy of undetermined significance (MGUS) but also other premalignant or early clonal disorders such as smoldering multiple myeloma (SMM), smoldering Waldenström macroglobulinemia (SWM), and monoclonal B-cell lymphocytosis, provided that the secreted monoclonal protein is directly responsible for renal injury [2]. Once the hematologic disorder progresses to MM, WM, advanced CLL, or malignant lymphoma, the condition is no longer classified as MGRS and treatment follows disease-specific oncologic protocols. Kidney involvement associated with monoclonal gammopathy is increasingly recognized in clinical practice. The spectrum of MGRS-associated nephropathies continues to expand and includes glomerular, tubulointerstitial, and vascular lesions, occurring either in isolation or combination. Accurate diagnosis requires establishing (i) the presence of a monoclonal gammopathy, (ii) the underlying pathogenic clone, and (iii) the specific pattern of renal injury [3]. Recent epidemiologic data indicate that patients with MGRS have a significantly higher risk of progression to MM compared with MGUS: Steiner et al. reported a median progression time of 18.8 years, with a 10% progression risk within the first year in MGRS versus 1% in MGUS [4].
From a hematologic perspective, MGRS due to a plasma cell clone is typically characterized by <10>
The aim of this review is to provide a comprehensive, clinically oriented overview of monoclonal gammopathy of renal significance, focusing on:
Particular emphasis is placed on integrating nephrologic and hematologic perspectives to support timely recognition and optimal management of this increasingly relevant clinical entity.
MGRS results from the deposition of monoclonal immunoglobulins (Ig) and light or heavy chain (LC or HC) fragments of various sizes released by plasma cells or plasmoblasts that proliferate clonally, possibly under the influence of helper T lymphocytes [5]. Immunoglobulins consist of two heavy (H) chains and two light (L) chains, where the L chain can be either κ (kappa) or λ (lambda). Each component chain contains an NH2-terminal "variable (V) IgSF" domain and one or more COOH-terminal "constant" (C) IgSF domains, each consisting of two β-sheets connected by a disulfide bridge between conserved cysteine residues [6]. Similar to HC, the two LC in a single Ig are identical. Mammals have two types of light chains, λ (lambda) and κ (kappa), with each Ig containing only one type. Each LC has a constant domain followed by a variable domain, approximately 215 amino acids in length [7]. About 30% of nephrotoxic free light chains (FLCs) secreted by plasma cell dyscrasias cause glomerular disease. Recent experiments have shown that specific monoclonal FLCs can cause glomerular lesions, including both light chain-associated (AL) amyloidosis and light chain deposition disease (LCDD) in animal models [8, 9, 10]. A study by Tang et al. revealed that most patients with MGRS had amyloidosis (n = 25), followed by cryoglobulinemic glomerulonephritis (cryo-GN, n = 7), proliferative glomerulonephritis with monoclonal IgG deposition (PGNMID, n = 5), and monoclonal immunoglobulin deposition disease (MIDD, n = 3) [12]. Table 1 presents the classification of renal lesions associated with monoclonal gammopathy of renal significance.
Pathogenesis of AL Amyloidosis
AL amyloidosis is an indolent plasma cell disorder characterized by the misfolding of free light chains (FLC) and the deposition of amyloid fibrils in various tissues [13]. The plasma cell clone in AL amyloidosis is typically small and indolent, secreting light chains in 75–80% of cases, and exhibits phenotypic and copy number alterations similar to those seen in multiple myeloma (MM) clones [18]. In AL amyloidosis, amyloid fibrils derived from monoclonal immunoglobulin light chains accumulate in multiple organs such as the heart, kidneys, liver, gastrointestinal tract, and peripheral nerves, causing diverse clinical manifestations [14,15]. The deposition of amyloid fibrils disrupts tissue architecture and cell membranes, and increased oxidative stress and proteotoxicity arise due to the action of amyloid oligomers [19,20]. Studies on immunoglobulin light chains suggest that specific IgL germline gene usage and point mutations in the IgL locus may predict organ tropism and fibril-forming propensity in AL amyloidosis [15]. Bochtler et al. first reported in 2015 that t(11;14) is associated with poorer outcomes in patients receiving bortezomib-based regimens [16]. Patients with t(11;14) also benefit from high dose melphalan chemotherapy followed by autologous stem cell transplantation (ASCT), with significantly higher response rates, better hematologic event-free survival, and a tendency for improved overall survival. Multivariate analysis identified t(11;14) as a favorable prognostic factor for hematologic event-free survival in patients treated with HDM+ASCT [17].
Histologic subtypes of renal involvement in AL amyloidosis have important prognostic and therapeutic implications [124].
Pathogenesis of Monoclonal Fibrillary Glomerulonephritis
Fibrillary glomerulonephritis (FGN) is a rare glomerular disease first described by Rosenmann and Eliakim in 1977 [21]. It is characterized by the accumulation of randomly arranged, straight fibrils in the glomeruli, which have a thickness of 12-24 nm under electron microscopy [22]. Most cases of FGN exhibit mesangial expansion, with or without glomerular basement membrane (GBM) duplication, and are less frequently associated with endocapillary hypercellularity or crescentic glomerulonephritis. Immunofluorescence typically shows a "smeared" granular staining for immunoglobulin G (IgG), which may be polyclonal, oligoclonal, or monoclonal, along with complement deposition (predominantly C3, and occasionally C1q) [23]. Studies indicate that approximately 10% of FGN patients have a monoclonal gammopathy, and it is now standard practice to screen these patients for monoclonal gammopathies [24]. DNAJB9, a heat shock protein found in the endoplasmic reticulum and involved in the endoplasmic reticulum stress/unfolded protein response (UPR) pathway, has been detected in glomeruli in renal biopsy samples using liquid chromatography and mass spectrometry [25]. However, local activation of the UPR pathway does not seem to drive the pathogenesis of FGN. One proposed mechanism is that increased circulating levels of DNAJB9, along with an autoantibody response in the glomeruli, results in an excess of DNAJB9 [26].
Pathogenesis of Immunotactoid Glomerulonephritis
Immunotactoid glomerulopathy (ITG) is a rare form of glomerulonephritis associated with proteinuria, hematuria, and renal insufficiency. Electron microscopy reveals characteristic microtubular deposits with diameters ranging from 14-60 nm, often arranged in parallel and predominantly located outside the lamina densa of the glomerular basement membrane. Immunofluorescence typically shows IgG-dominant staining, which in 67% of cases is restricted to light chains and IgG subclasses, indicating a monoclonal composition. Monoclonal ITG is more frequently associated with lymphoma (53% vs. 11%), multiple myeloma (8% vs. 0%), and monoclonal gammopathy (22% vs. 16%) compared to polyclonal ITG [27].
Pathogenesis of Cryoglobulinemic Glomerulonephritis
Cryoglobulinemic glomerulonephritis is characterized by the intraglomerular deposition of immune complexes, complement activation, leukocyte influx, and glomerular remodeling [28]. Brouet et al. classified cryoglobulins into three subtypes based on immunofixation: Type I consists solely of monoclonal immunoglobulins (paraproteins); Type II includes both monoclonal and polyclonal immunoglobulins; and Type III contains only polyclonal immunoglobulins. Types II and III are often referred to as mixed cryoglobulinemia due to their overlapping clinical presentations and pathophysiology [29]. Type II cryoglobulinemia represents the most common subtype of cryoglobulin-associated disorders, accounting for approximately 50–65% of all cases [30]. Type III cryoglobulins, which contain mixed polyclonal IgM and IgG components, account for 25-40% of cases and are often associated with autoimmune diseases or infections such as hepatitis C [31]. Renal involvement occurs in about 29% of patients with cryoglobulinemia, being most common in patients with Type II cryoglobulins (approximately 84%) and rare in those with Type I (about 4%) and Type III cryoglobulins (about 11%) [32]. Aberrant B-cell function and lymphoproliferation are key factors associated with cryoglobulin production, especially in patients infected with the hepatitis C virus. Hepatitis C virus enters B cells via the CD81 receptor, which is present on both hepatocytes and B cells, leading to infection and subsequent dysfunction and proliferation of B cells, which release mixed cryoglobulins into the circulation [33].
Pathogenesis of Light Chain Proximal Tubulopathy
Light chain proximal tubulopathy (LCPT) is characterized by the cytoplasmic accumulation of monoclonal light chains within proximal tubule cells. LCPT is most commonly caused by light chains of the kappa-I (κI) subgroup, which are inadequately degraded by lysosomes. These abnormal, truncated kappa light chains fail to bind to Tamm-Horsfall glycoprotein, which is why light chain cast nephropathy is not typically associated with this condition.[34] A hallmark of LCPT is the crystallization of κ-light chains within the proximal tubules, and this condition is associated with Fanconi syndrome in approximately 40% of patients. [35]. LCPT without crystals can be linked to either κ- or λ-light chain accumulation. The excessive light chains absorbed into the cytoplasm of proximal tubule cells lead to the formation of crystalline structures that can be identified via immunofixation and electron microscopy. These crystals are electron-dense, typically exhibiting a rhomboid, square, or rectangular shape, and can be found within the lysosomes of proximal tubule cells [36]. Patients with LCPT generally present with a subacute decline in renal function and low-grade proteinuria. The renal impairment can be mild and progress slowly over the course of several years, though renal failure is also possible.[37]
Pathogenesis of Crystal-Storing Histiocytosis
Crystal-storing histiocytosis is characterized histologically by intracellular crystalline inclusions within histiocytes, which accumulate and affect various organs throughout the body. It is commonly associated with lymphoproliferative disorders, particularly those with plasmacytic differentiation, including multiple myeloma, lymphoplasmacytic lymphoma, marginal zone lymphoma with plasmacytic differentiation, and monoclonal gammopathy of undetermined significance. [38]
Pathogenesis of Monoclonal Immunoglobulin Deposition Disease (MIDD)
Monoclonal immunoglobulin deposition disease (MIDD) encompasses a group of disorders characterized by the linear deposition of monoclonal light chains (LCDD), heavy chains (HCDD), or both (LHCDD) along basement membranes, most commonly in the kidney. Unlike AL amyloidosis, MIDD deposits are non-fibrillar and Congo-red negative, but share the same underlying mechanism of monoclonal gammopathy [122]. Renal involvement typically manifests with proteinuria, often in the nephrotic range, and progressive renal insufficiency. Histologically, thickening of glomerular and tubular basement membranes is observed, with nodular glomerulosclerosis resembling diabetic nephropathy. Diagnosis is confirmed by immunofluorescence and electron microscopy, revealing the nature and localization of the deposits. Effective treatment requires prompt clone-directed therapy. Bortezomib-based regimens have shown excellent hematologic and renal responses [123]. Autologous stem cell transplantation (ASCT) can be useful as a therapeutic strategy in MIDD.
C3-Glomerulopathy with Monoclonal Gammopathy
C3 glomerulopathy (C3G) is a rare and heterogeneous group of glomerular diseases characterized by predominant C3 deposition in the glomeruli without significant immunoglobulin deposits. It includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). In the context of MGRS, C3G can result from a monoclonal gammopathy-induced dysregulation of the alternative complement pathway. Monoclonal immunoglobulins may act as autoantibodies against complement regulatory proteins such as factor H or factor I, or serve as nephritic factors stabilizing C3 convertase. Diagnosis requires renal biopsy with immunofluorescence and electron microscopy. Complement studies and serum monoclonal protein evaluation are essential. Evidence of a pathogenic monoclonal clone should prompt clone-directed therapy, although data on optimal management remain limited [47].
| Monoclonal immunoglobulin deposits | |||
| Fibrillar | Microscopic patterns | Monoclonal Protein | Organ damage |
| AL amyloidosis | Congo red positive
fibrils (7-12 nm) | FLC (λ > κ) | affects heart, kidney,liver |
Monoclonal fibrillary GN | Congo red negative
fibrils (10-30 nm) | IgG, C3, κ/λ deposits
| Kidney |
| Microtubular | |||
Immunotactoid GN
| Coarse microtubules (17-52 nm)
| mesangial IgG, C3, parallel arrays
| Kidney |
| Crioglobulinemic GN | not organized deposits | includes IgM/IgG, C3, sometimes crystalline
| Kidney |
| Crystalline or inclusion-forming lessions | |||
| Light chain proximal tubulopathy | cristalline (κ, Fanconi
non-crystalline (λ, rare | LC inclusions within tubular epithelium
| Kidney |
| Crystal storing hystiocytosis | histiocytes with LC crystals
| LC crystalloid inclusions within macrophages/histiocytes BM, LN, lungs | Kidney, lung |
| Not organized | |||
Monoclonal immunoglobulin Deposition disease (MIDD) | Light or heavy chains distributed along GBM and TBM IgG1 | LCDD: mesangial and/or glomerular basement membrane monoclonal LC deposits HCDD: k and l negative, staining for 1 of the immunoglobulins (most commonly IgG or IgM) | Kidney, Liver, Heart |
Proliferative GN with monoclonal deposits (PGNMID)
| IgG/LC deposits with proliferative GN pattern | monoclonal immunoglobulin or, more rarely, monoclonal LC deposits
| Kidney |
| Complement-mediated (without direct Ig deposits) | |||
C3 glomerulopathy
| Monoclonal gammopathy detectable in 60-80% of individuals >50 years with C3 glomerulonephritis | Granular, C3-dominant deposits
| Kidney |
| Thrombotic microangiopathy (TMA) provisional | |||
| POEMS | provisional | ||
| Monoclonal immunoglobulin deposits | |||
| Fibrillar | Microscopic patterns | Monoclonal Protein | Organ damage |
| AL amyloidosis | Congo red positive Fibrils (7-12 nm) | FLC (λ > κ) | affects heart, kidney, liver |
Monoclonal fibrillary GN | Congo red negative Fibrils (10-30 nm) | IgG, C3, κ/λ deposits
| Kidney |
| Microtubular | |||
Immunotactoid GN
| Coarse microtubules (17-52 nm) | Mesangial IgG, C3, parallel arrays
| Kidney |
| Crioglobulinemic GN | Not organized deposits | includes IgM/IgG, C3, sometimes crystalline
| Kidney |
| Crystalline or inclusion-forming lessions | |||
| Light chain proximal tubulopathy | Cristalline (κ, Fanconi
non-crystalline (λ, rare | LC inclusions within tubular epithelium
| Kidney |
| Crystal storing hystiocytos | Histiocytes with LC crystals
| LC crystalloid inclusions within macrophages/histiocytes BM, LN, lungs | Kidney, lung |
Table 1: Classification of monoclonal gammopathy of renal significance-associated renal lesions
Abbreviations: BM, bone marrow; GBM, glomerular base membrane; LN, lymph node; TBM, tubular base membrane
* Adapted from [2].
Due to the differences in clinical presentation, prognosis, and therapeutic strategies, it is essential to distinguish MGUS-associated findings from renal diseases that are not caused by monoclonal immunoglobulins [51]. The diagnostic work-up of suspected MGRS consists of four core steps:
Several laboratory findings increase the pretest probability of MGRS, including urinary protein excretion >1.5 g/day, an abnormal serum free light chain (FLC) ratio, and microscopic hematuria. In patients with monoclonal gammopathy and these abnormalities or in those with otherwise unexplained acute or progressive renal dysfunction a renal biopsy should be performed early [50]. Despite this, renal biopsy remains underused: in one multicenter study, only 12.9% of patients with monoclonal gammopathy and renal impairment underwent kidney biopsy, yet over 40% of those biopsied had lesions unrelated to their monoclonal gammopathy, with amyloid nephropathy being the most common [52]. Given the prognostic impact of renal function and the low complication rate of native kidney biopsy, this procedure is considered safe and essential to establish a correct diagnosis and should be strongly recommended in all patients with suspected MGRS [52]. In selected high-risk cases, a transjugular renal biopsy allows safe tissue acquisition when percutaneous biopsy poses unacceptable risk [53]. Detection of monoclonal immunoglobulin deposits in renal tissue confirms the presence of a pathogenic B-cell or plasma cell clone. Therefore, once a monoclonal deposit is identified, further efforts must focus on precise immunophenotypic and molecular characterization of the clone, as this directly determines treatment strategy [54]. Biochemical detection of monoclonal proteins requires a combination of serum and urine studies. Serum protein electrophoresis (SPE), with a detection limit of 500-2000 mg/L, lacks sufficient sensitivity—especially for free light chains, which have short plasma half-lives. In contrast, the serum free light chain assay (sFLC) achieves sensitivity below 5 mg/L, making it indispensable for detecting subtle abnormalities in free light chain synthesis [57]. However, SPE should be complemented by serum and urine immunofixation, which are more sensitive for identifying intact monoclonal immunoglobulins and allow determination of the isotype even when SPE is inconclusive [55]. Serum immunofixation is roughly ten times more sensitive than SPE, yet urine immunofixation or sFLC measurement is often required to detect low level monoclonal proteins [56]. Although urine electrophoresis is the least sensitive assay for detecting monoclonal gammopathy—since only free light chains are filtered through the glomerulus—its diagnostic value remains high because it reliably distinguishes cast nephropathy (dominant light chains) from AL amyloidosis/MIDD (selective albuminuria). It also provides quantitative information on total and albumin protein excretion, which assists in diagnosis, prognostication, and response assessment [58]. Once a monoclonal protein has been identified, clone characterization becomes essential. Plasma cell derived clones (typically producing κ or λ light chains) require myeloma based treatment algorithms, whereas lymphoplasmacytic or B-cell clones (e.g., IgM-producing clones) often demand anti-CD20 based therapy or lymphoma directed regimens [59]. Despite growing recognition of MGRS as a distinct entity, no universally accepted renal response criteria exist across its histologic subtypes. This lack of standardization limits the comparability of clinical studies and complicates assessment of treatment efficacy [2,54]. In contrast, AL amyloidosis benefits from well validated and broadly accepted organ response criteria, a model underscoring the need for uniform, subtype specific renal endpoints in MGRS.
The treatment of MGRS is aimed at targeting the causative B-cell or plasma cell clone. The therapeutic management of monoclonal gammopathy of renal significance (MGRS) requires an integrated and clone-directed approach that combines insights from hematology, nephrology, and histopathology. Rather than listing available agents in isolation, therapy should be structured according to the underlying pathogenesis, histological lesion, and type of monoclonal clone (plasma cell vs. B-cell origin), while taking into account the extent of renal and extrarenal involvement. MGRS comprises a heterogeneous group of renal diseases caused by nephrotoxic monoclonal immunoglobulins or their fragments secreted by small, otherwise non-malignant B-cell or plasma cell clones. The pathological spectrum includes amyloid forming disorders (e.g., AL amyloidosis), non-fibrillar immunoglobulin deposition diseases (e.g., LCDD, HCDD), and complement-mediated glomerulopathies (e.g., C3 glomerulopathy), among others. These entities are unified by the presence of a monoclonal protein that leads to organ damage despite the absence of overt hematologic malignancy [2,5]. Diagnostic evaluation should aim to identify the responsible clone through serum and urine protein electrophoresis, immunofixation, serum free light chain analysis, and bone marrow biopsy. Renal biopsy is essential to confirm the lesion and detect monoclonal deposits via immunofluorescence and electron microscopy. Clone characterization is critical for treatment selection: plasma cell derived lesions (e.g., AL, LCDD) are treated with myeloma type regimens, whereas B-cell driven disorders (e.g., PGNMID, immunotactoid GN) often respond to rituximab based therapies [2,3,54]. The therapeutic goal is to preserve renal function and prevent systemic progression by achieving deep and durable hematologic responses. Agents must be selected based on efficacy and tolerability in patients with renal impairment. Proteasome inhibitors (e.g., bortezomib, ixazomib), monoclonal antibodies (e.g., daratumumab, rituximab), and immunomodulatory drugs (e.g., lenalidomide, pomalidomide) are central to most regimens. Novel agents such as venetoclax, teclistamab, and CAR-T cells are increasingly relevant, especially in relapsed or refractory disease and in genetically defined subgroups (e.g., t (11;14)) [69,70,109]. Importantly, treatment response should be monitored using both hematologic and organ-specific parameters, as hematologic remission often precedes renal improvement. The lack of uniform renal response criteria across MGRS subtypes remains a major limitation in clinical evaluation and trial design [2,54].
By embedding therapeutic decisions in a pathophysiological and diagnostic framework, clinicians can better tailor interventions to disease biology and improve long term outcomes in MGRS.
Figure 1: Proposed workflow. Diagnostic and therapeutic algorithm in MGRS, stratified by by clonal origin and renal lesion type. [2]
4.1. Treatment of Newly Diagnosed AL Amyloidosis
The primary therapeutic objective in newly diagnosed AL amyloidosis is the rapid suppression of amyloidogenic free light chains to prevent irreversible organ damage. Treatment selection depends on transplant eligibility, organ involvement and patient frailty. In transplant eligible patients, high dose melphalan followed by autologous stem cell transplantation (HDM/ASCT) remains the standard of care. When appropriately selected, this approach leads to high hematologic complete response (CR) rates and long-term survival benefit. However, treatment-related mortality remains significant in patients with cardiac involvement and poor performance status, underscoring the need for careful pre-transplant risk stratification [67,68]. For transplant ineligible patients, the combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) has become the frontline standard. The phase III ANDROMEDA trial demonstrated superior hematologic and organ response rates with Dara-CyBorD compared to CyBorD alone. Hematologic CR was achieved in 53% of patients, and 79?hieved a very good partial response (VGPR) or better [72]. Daratumumab is safe and effective even in patients with severe renal impairment or dialysis dependency [97]. Bortezomib, given subcutaneously once weekly, is favored for its efficacy and tolerability in renal dysfunction. Cyclophosphamide and dexamethasone contribute synergistically with minimal additional toxicity.[74]
4.2. Treatment of Relapsed or Refractory AL Amyloidosis
In relapsed or refractory AL amyloidosis, treatment choice is guided by prior therapy, duration and depth of response, cytogenetic features, and organ reserve. Pomalidomide, a third-generation IMiD, has demonstrated efficacy in patients previously exposed to proteasome inhibitors. In a European multicenter retrospective study, pomalidomide with dexamethasone achieved a hematologic response in 55–65% of patients, with median progression-free survival (PFS) of up to 37 months among responders [93]. Ixazomib, an oral proteasome inhibitor, offers an attractive alternative for frail patients. In the TOURMALINE-AL1 trial, ixazomib/dexamethasone showed comparable hematologic response rates to physician’s choice (53% vs. 51%) but was associated with longer organ PFS and improved tolerability [87]. For patients with the t(11;14) translocation, venetoclax - a selective BCL-2 inhibitor - has shown outstanding efficacy. A retrospective cohort study reported hematologic response rates of 81%, with deep remissions (VGPR or better in 78%) and organ response in 83% of evaluable patients [109]. In heavily pretreated or refractory disease, emerging immunotherapies show promising potential. Teclistamab, a bispecific antibody targeting BCMA, achieved 100% VGPR or better in a small cohort of AL amyloidosis patients [69]. Anti-BCMA CAR-T cells have also demonstrated remarkable hematologic responses and organ improvement in selected patients, with acceptable toxicity profiles [70]. While AL amyloidosis is typically caused by a small plasma cell clone secreting free light chains, a subset of cases arises from a B-cell or lymphoplasmacytic clone producing intact monoclonal IgM or IgG. This clonal origin has important clinical and therapeutic implications. Plasma cell-associated AL amyloidosis accounts for the vast majority of cases and responds well to antimyeloma regimens such as bortezomib based combinations, daratumumab, or high dose melphalan with autologous stem cell transplantation [65,72]. In contrast, B-cell driven AL amyloidosis, which constitutes approximately 5-7% of cases, is often associated with lymphoplasmacytic lymphoma or other indolent B-cell neoplasms. These patients typically produce monoclonal IgM and require treatment with anti-CD20-based regimens such as rituximab plus bendamustine or BTK inhibitors in selected cases [107]. Given the overlapping histologic features but divergent therapeutic approaches, accurate clone identification via bone marrow biopsy and immunophenotyping is critical prior to initiating therapy.
4.3. Novel Agents in the Therapy of AL Amyloidosis
Proteasome Inhibitors
Bortezomib
Bortezomib is effective and well tolerated by patients with impaired renal function, including those requiring dialysis [75]. It is administered as a single agent or in combination with dexamethasone and alkylating agents (e.g., melphalan, cyclophosphamide) [76]. For AL amyloidosis, subcutaneous bortezomib once weekly, with a risk-adapted dosage, is typically preferred [77]. Bortezomib is suspected of causing cardiotoxicity, so it should be used with caution, especially in the presence of cardiac involvement [78]. The pharmacokinetics of bortezomib are not affected by the degree of renal dysfunction, as its primary metabolic pathway is oxidative deboronation via hepatic cytochrome P450 enzymes [79]. No dose adjustment is necessary in patients with impaired renal function. Bortezomib is not recommended for patients with peripheral polyneuropathy [80].
Carfilzomib
Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds with greater affinity to the 5-proteasome subunit and the LMP7 subunit of the immunoproteasome compared to bortezomib [83]. According to available pharmacokinetic data, no initial dose adjustment is required for patients with mild, moderate, or severe renal impairment, or for those undergoing chronic dialysis therapy [84]. In AL amyloidosis, carfilzomib should be used with caution due to documented cardiac, pulmonary, and renal toxicities, especially in patients with multiple organ involvement. However, in a small group of patients without cardiac deposits and with peripheral neuropathy, carfilzomib was well tolerated and highly effective [85].
Ixazomib
Ixazomib is an oral, highly selective, and reversible proteasome inhibitor. It preferentially binds to and inhibits the chymotrypsin-like activity of the beta-5 subunit of the 20S proteasome. This results in the disruption of cellular regulatory mechanisms, which in turn inhibits cell growth and survival pathways, ultimately leading to apoptosis [86]. In the TOURMALINE-AL1 trial, ixazomib combined with dexamethasone did not show a higher rate of hematologic responses (53% vs. 51%) and did not meet the primary endpoint. However, several key secondary endpoints were met, including time to vital organ deterioration or death (35 vs. 26 months) and the hematologic complete response (CR) rate (26% vs. 18%). Hematologic responses were prolonged in the ixazomib/dexamethasone arm compared to the physician’s choice arm (46.5 vs. 20.2 months). Additionally, the progression-free survival (PFS) of vital organs was also longer in the ixazomib/dexamethasone arm (18 vs. 11 months) [87]. Whether ixazomib is the preferred proteasome inhibitor in newly diagnosed AL amyloidosis with higher efficacy or a better safety profile needs further investigation. A phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis (NCT03236792) demonstrated the safety and efficacy of the oral IxaCyD regimen. In the phase 1/2 intention-to-treat (ITT) population, an overall hematologic response rate of 55% was observed. With the recommended phase 2 dose (RP2D) (Ixa, 4 mg; Cy, 500 mg; D, 20 mg), 64% of patients achieved a hematologic response, including 57% who rapidly achieved a very good partial response (VGPR) after a mean of 1.5 cycles. This response resulted in renal responses in 50% of evaluable RP2D patients at 6 months, but only 22% showed cardiac responses at the same time point. This study demonstrated that IxaCyD is a safe and effective all-oral induction regimen for treatment-naïve patients with AL amyloidosis [88].
Thalidomide
Thalidomide is associated with significant toxicities, particularly in AL amyloidosis with cardiac involvement (e.g., bradycardia and cardiac arrhythmia). Thalidomide should be avoided in patients with AL and pre-existing peripheral neuropathy (PNP) [76].
Lenalidomide
Lenalidomide is a second generation immunomodulatory drug (IMiD) used for treating patients with relapsed or refractory myeloma. Lenalidomide was combined with melphalan/dexamethasone or cyclophosphamide/dexamethasone at lower than standard doses, resulting in hematologic responses in 38-68% of previously untreated patients and 46-60% in patients refractory to bortezomib, thalidomide, and alkylating agents [89,90]. The median dose of lenalidomide was 10 mg per day (maximum 15 mg). Treatment discontinuations were frequent [91]. Lenalidomide-associated toxicities in AL amyloidosis patients include myelosuppression, skin rashes, infections, thrombotic complications, and fatigue.
Pomalidomide
Pomalidomide is an IMiD developed after thalidomide and lenalidomide. Before excretion, pomalidomide is mainly metabolized by CYP450 in the liver, and unlike lenalidomide, only 2% of unmetabolized pomalidomide is excreted in the urine [92]. Most patients exhibit an initial response after one cycle of therapy. Hematologic response was associated with improved overall survival (median survival: 50 vs. 27 months). At least partial hematologic responses were linked to significantly longer progression-free survival (PFS) (median PFS: 37 vs. 18 months). Grade 3 adverse events were documented in 33% of patients, with the most common adverse events being infections (9%), heart failure (7%), an increase in creatinine (6%), and cytopenia (2%) [93].
Iberdomide and Megzidomide are not yet approved for the treatment of MGRS.
Monoclonal Antibodies
Daratumumab
Daratumumab is a human monoclonal IgG1-κ antibody that binds to a single CD38 epitope [94]. In the phase 3 ANDROMEDA study, daratumumab subcutaneously combined with CyBorD (cyclophosphamide, bortezomib, dexamethasone) was compared with CyBorD in first-line therapy. The safety run-in phase demonstrated an excellent overall response rate of 96% in the Dara-CyBorD arm, with 82?hieving a very good partial response (VGPR). The study also showed that daratumumab plus CyBorD was well tolerated by previously untreated AL amyloidosis patients [73,95]. Based on these data, daratumumab was approved by the US FDA on January 15, 2021, for the treatment of AL amyloidosis. Notably, no new safety signals were observed, and daratumumab can be safely administered to patients with severe renal impairment (RI) or dialysis-dependent patients [97].
Isatuximab
Isatuximab is a chimeric mouse/human IgG1k monoclonal antibody targeting CD38 on both malignant and normal plasma cells. Its antitumor effect primarily results from antibody dependent cell mediated cytotoxicity. The efficacy of isatuximab in relapsed or refractory AL amyloidosis and MGRS is currently under investigation [96].
Elotuzumab
Elotuzumab is a humanized immunostimulatory IgG1 monoclonal antibody targeting the lymphocyte signaling activation molecule F7 (SLAMF7, also known as CS1), a glycoprotein expressed in myeloma and natural killer cells but not in normal tissue [98]. Elotuzumab combined with lenalidomide and dexamethasone showed a significant hematologic response in a patient with relapsed/refractory multiple myeloma (RRMM) and kFLC amyloidosis. This treatment combination alone may be effective in primary amyloidosis and warrants further investigation [99].
4.4. T-cell redirection therapies
Monoclonal Antibodies Targeting BCMA
Teclistamab
Teclistamab is a bispecific T-cell engager antibody that binds to B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, thereby redirecting cytotoxic T cells to eliminate BCMA-expressing clonal plasma cells. Although originally developed for relapsed/refractory multiple myeloma, recent evidence supports its use in systemic AL amyloidosis. In a retrospective multicenter study, Chakraborty et al. evaluated seven patients with relapsed AL amyloidosis treated with teclistamab, all of whom achieved a hematologic response of VGPR or better (100%), with rapid and deep suppression of free light chains and early organ response [69]. In a recent multinational retrospective case series evaluating teclistamab in relapsed or refractory AL amyloidosis, Forgeard et al. reported encouraging safety and efficacy signals in a heavily pretreated patient population. Importantly, no unexpected toxicity signals were observed, and cytokine release syndrome and neurotoxicity were manageable. These findings suggest that teclistamab may represent a promising therapeutic option for selected, heavily pretreated AL amyloidosis patients, particularly those who are ineligible for transplantation or refractory to conventional therapies [125].
Chimeric Antigen Receptor (CAR) T-Cells
T-cell therapy with chimeric antigen receptors (CARs) has emerged as a novel approach with the potential to provide long-term disease control in patients with some types of hematologic cancers. Anti-CD19 CAR-T cell therapies have been shown to be effective in patients with leukemia or lymphoma [104,105]. In a prospective study, clonal plasma cells from patients with AL amyloidosis were found to express low levels of BCMA but high levels of SLAMF7. SLAMF7 CAR-T cells showed antitumor activity in an AL amyloidosis model in a preclinical study. SLAMF7 CAR-T cells were injected into xenograft models of AL amyloidosis [106]. This suggests that CAR-T cells could have a role, particularly for a subset of AL amyloidosis patients. IgM AL amyloidosis, caused by an underlying lymphoproliferative/lymphoplasmacytic B-cell clone secreting intact IgM, occurs in 5-7% of cases [107]. Ongoing clinical trials are expanding the spectrum of disease to include indolent lymphomas.
Venetoclax
Venetoclax is a highly selective and potent oral BCL-2 inhibitor that induces apoptosis in multiple myeloma cell lines and primary multiple myeloma cells [108]. A retrospective study of 43 patients with relapsed/refractory AL showed that patients with t(11;14) had a higher overall hematologic response rate (81% vs. 40%) and a higher CR/VGPR rate (78% vs. 30%). The study also demonstrated a high rate of organ response (83% vs. 17%) and a reduced risk of progression or death (HR: 0.292, 95% CI: 0.046–1.855, p = 0.192) [109].
4.5. Therapy of MIDD
Small retrospective studies have suggested that HDM/ASCT is a good treatment option with high hematologic response rates and low treatment-related mortality [110]. Preliminary results suggest that bortezomib-based therapies may yield similar hematologic response rates to HDM/ASCT, as seen in multiple myeloma [111]. In patients with stage 1 to 3 chronic kidney disease (CKD), the primary goal is to preserve renal function. Bortezomib-based treatment, such as CyBorD, is recommended as initial treatment. HDM/ASCT should then be considered in selected patients who are in good general condition and lack significant extrarenal manifestations, particularly if they have only achieved a partial hematologic response to initial treatment. For patients with stage 4 and 5 CKD, the likelihood of renal recovery is low. In such patients who are not candidates for kidney transplantation, the primary goal is to preserve extrarenal organs, especially the heart. Bortezomib-based therapy, such as CyBorD, is recommended. If renal transplantation is planned, the therapeutic goal is long-term preservation of allograft function, requiring an optimal clonal response. In this case, HDM/ASCT should be considered after 3 to 4 cycles of CBD-like therapy [112].
Type I Cryoglobulinemia
Type I cryoglobulinemia is typically associated with a monoclonal IgG, IgA, or IgM produced by an underlying plasma cell or B-cell clone. Management is dictated by the severity of systemic manifestations and the nature of the clonal disorder. Patients with mild symptoms and low-grade clonal proliferation may be monitored with serial renal assessments. Cold avoidance and symptomatic treatment remain essential. Treatment is indicated in patients with progressive vasculopathy, hyperviscosity, or renal involvement.
Plasma cell driven type I cryoglobulinemia (usually IgG/IgA):
Therapy should follow myeloma type regimens. Bortezomib-, cyclophosphamide-, and thalidomide based therapies are effective in rapidly reducing cryoglobulin production and stabilizing renal function.
Rituximab is not effective in this subtype because the pathogenic clone is not CD20-positive [132].
Lymphoplasmacytic / IgM-associated type I cryoglobulinemia:
Treatment should align with WM or IgM driven MGRS, typically rituximab containing therapy, combined with steroid premedication to minimize IgM flare. Bendamustine-rituximab is appropriate in progressive disease and remains safe in renal impairment [133].
Type I cryoglobulinemia due to underlying CLL or B-cell lymphoma:
Treatment should follow CLL/lymphoma protocols using anti-CD20 antibodies combined with cytotoxic agents as indicated [54].
Cyclophosphamide dose reduction is required when GFR <20>
Plasma exchange may be considered for patients with severe hyperviscosity or rapidly progressive vasculitis while clone directed therapy is initiated.
Type II Cryoglobulinemia
Most cases are associated with chronic hepatitis C virus (HCV) infection [114]. Antiviral therapy should be administered to all patients with symptomatic type II cryoglobulinemia linked to chronic HCV infection. In patients with symptomatic vasculitis, antiviral therapy should be combined with rituximab. Complete plasma exchange should also be considered in patients with rapidly progressive renal disease and/or severe organ involvement [115]. For patients without detectable viral replication but who experience episodic purpuric relapses, monitoring alone is recommended. For recurrent symptoms or renal involvement, rituximab is the treatment of choice [116]. Chemotherapy should be considered in patients with manifest Waldenström's disease or B-cell lymphoma, particularly if symptoms are more severe than occasional purpura, regardless of their HCV status. The treatment regimen should be adjusted based on the underlying B-cell clone and renal function [117].
Immunotactoid Glomerulopathy
Glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits is often associated with CLL or small lymphocytic lymphoma in more than half of cases, while a low-grade plasma cell clone is less common. Although therapy selection is based on limited case series, treatment adapted to CLL should be proposed for most patients. In severe CKD, cyclophosphamide- and/or bendamustine-based therapies, including corticosteroids, may be recommended. In patients with manifest CLL, rituximab should be considered. In cases of gammopathy, the role of rituximab is uncertain, and bortezomib-based therapy may be an option [118].
PGNMID
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) represents a heterogeneous MGRS entity in which therapeutic decisions depend on the nature of the underlying clone. In patients with stage 1-2 CKD and non-progressive low grade proteinuria (<1>1 g/day, declining renal function, or stage 3-4 CKD generally require clone-directed therapy. For plasma cell driven PGNMID, cyclophosphamide–bortezomib–dexamethasone (CBD-like therapy) is widely utilized due to its rapid cytoreductive effect, favorable renal tolerability, and high rates of hematologic response [127]. The term “CBD-like” refers to combinations structurally equivalent to CyBorD but adjusted for renal insufficiency. Bortezomib, as a proteasome inhibitor with rapid activity and no need for renal dose adjustment, remains the cornerstone of therapy for plasma cell mediated MGRS lesions, including PGNMID and LCDD [128]. Subcutaneous once-weekly bortezomib is preferred in CKD to minimize neuropathy while preserving efficacy.
In patients with significant cytopenias, severe CKD, or frailty, CyBorD (cyclophosphamide, bortezomib, dexamethasone) is considered an optimal first-line option because of its predictable safety profile and effectiveness even in dialysis dependent patients [129]. Autologous stem cell transplantation (HDM/ASCT) may be considered in selected fit patients with plasma cell associated PGNMID, particularly when partial hematologic response persists after initial therapy [130].
B-cell / lymphoplasmacytic PGNMID
For patients with B-cell or lymphoplasmacytic clones (e.g., IgM PGNMID), rituximab based regimens constitute the foundation of therapy. Combination therapy (e.g., rituximab–bendamustine) may be necessary in proliferative or relapsing disease. Bendamustine is particularly valuable in advanced CKD because it is not renally excreted and requires no dose adjustment [131].
Acquired Fanconi Syndrome
In rare cases of symptomatic progression, steroids should be considered in addition to chemotherapy. For patients with stage 1 to 3 CKD, chemotherapy may help slow the progression of end-stage renal disease (ESRD). Cyclophosphamide-, bortezomib-, or thalidomide-based therapies are the best options, with bendamustine also being a viable alternative. HDM/ASCT may be considered for selected non-responding patients, though its benefit remains unproven. For patients with stage 4 to 5 CKD who are candidates for renal allograft transplantation, chemotherapy (including HDM/ASCT) should be considered before and/or after transplantation. For those not eligible for kidney transplantation, chemotherapy is not beneficial [54].
Monoclonal gammopathy of renal significance (MGRS) encompasses a heterogeneous group of kidney diseases caused by nephrotoxic monoclonal immunoglobulins produced by small B-cell or plasma cell clones that do not meet criteria for overt hematologic malignancy. Early recognition is essential, as renal injury can progress rapidly and become irreversible. A renal biopsy remains the cornerstone of diagnosis, allowing precise identification of the underlying lesion and its pathophysiological mechanism. Effective management requires close collaboration between nephrology and hematology to ensure timely, clone-directed therapy aimed at halting further organ damage and stabilizing or improving kidney function. Advances in diagnostic techniques and targeted treatments including novel immunotherapies are expanding therapeutic options and improving outcomes. Despite these developments, MGRS remains a progressive disorder if untreated, underscoring the importance of early diagnosis, individualized therapy, and ongoing multidisciplinary care.
This research received no external funding.
The authors declare no conflict of interest.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.
Dear Agrippa Hilda- Editorial Coordinator of Journal of Neuroscience and Neurological Surgery, "The peer review process was very quick and of high quality, which can also be seen in the articles in the journal. The collaboration with the editorial office was very good."
I would like to express my sincere gratitude for the support and efficiency provided by the editorial office throughout the publication process of my article, “Delayed Vulvar Metastases from Rectal Carcinoma: A Case Report.” I greatly appreciate the assistance and guidance I received from your team, which made the entire process smooth and efficient. The peer review process was thorough and constructive, contributing to the overall quality of the final article. I am very grateful for the high level of professionalism and commitment shown by the editorial staff, and I look forward to maintaining a long-term collaboration with the International Journal of Clinical Case Reports and Reviews.
To Dear Erin Aust, I would like to express my heartfelt appreciation for the opportunity to have my work published in this esteemed journal. The entire publication process was smooth and well-organized, and I am extremely satisfied with the final result. The Editorial Team demonstrated the utmost professionalism, providing prompt and insightful feedback throughout the review process. Their clear communication and constructive suggestions were invaluable in enhancing my manuscript, and their meticulous attention to detail and dedication to quality are truly commendable. Additionally, the support from the Editorial Office was exceptional. From the initial submission to the final publication, I was guided through every step of the process with great care and professionalism. The team's responsiveness and assistance made the entire experience both easy and stress-free. I am also deeply impressed by the quality and reputation of the journal. It is an honor to have my research featured in such a respected publication, and I am confident that it will make a meaningful contribution to the field.
"I am grateful for the opportunity of contributing to [International Journal of Clinical Case Reports and Reviews] and for the rigorous review process that enhances the quality of research published in your esteemed journal. I sincerely appreciate the time and effort of your team who have dedicatedly helped me in improvising changes and modifying my manuscript. The insightful comments and constructive feedback provided have been invaluable in refining and strengthening my work".
I thank the ‘Journal of Clinical Research and Reports’ for accepting this article for publication. This is a rigorously peer reviewed journal which is on all major global scientific data bases. I note the review process was prompt, thorough and professionally critical. It gave us an insight into a number of important scientific/statistical issues. The review prompted us to review the relevant literature again and look at the limitations of the study. The peer reviewers were open, clear in the instructions and the editorial team was very prompt in their communication. This journal certainly publishes quality research articles. I would recommend the journal for any future publications.
Dear Jessica Magne, with gratitude for the joint work. Fast process of receiving and processing the submitted scientific materials in “Clinical Cardiology and Cardiovascular Interventions”. High level of competence of the editors with clear and correct recommendations and ideas for enriching the article.
We found the peer review process quick and positive in its input. The support from the editorial officer has been very agile, always with the intention of improving the article and taking into account our subsequent corrections.
My article, titled 'No Way Out of the Smartphone Epidemic Without Considering the Insights of Brain Research,' has been republished in the International Journal of Clinical Case Reports and Reviews. The review process was seamless and professional, with the editors being both friendly and supportive. I am deeply grateful for their efforts.
To Dear Erin Aust – Editorial Coordinator of Journal of General Medicine and Clinical Practice! I declare that I am absolutely satisfied with your work carried out with great competence in following the manuscript during the various stages from its receipt, during the revision process to the final acceptance for publication. Thank Prof. Elvira Farina
Dear Jessica, and the super professional team of the ‘Clinical Cardiology and Cardiovascular Interventions’ I am sincerely grateful to the coordinated work of the journal team for the no problem with the submission of my manuscript: “Cardiometabolic Disorders in A Pregnant Woman with Severe Preeclampsia on the Background of Morbid Obesity (Case Report).” The review process by 5 experts was fast, and the comments were professional, which made it more specific and academic, and the process of publication and presentation of the article was excellent. I recommend that my colleagues publish articles in this journal, and I am interested in further scientific cooperation. Sincerely and best wishes, Dr. Oleg Golyanovskiy.
Dear Ashley Rosa, Editorial Coordinator of the journal - Psychology and Mental Health Care. " The process of obtaining publication of my article in the Psychology and Mental Health Journal was positive in all areas. The peer review process resulted in a number of valuable comments, the editorial process was collaborative and timely, and the quality of this journal has been quickly noticed, resulting in alternative journals contacting me to publish with them." Warm regards, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. I appreciate the journal (JCCI) editorial office support, the entire team leads were always ready to help, not only on technical front but also on thorough process. Also, I should thank dear reviewers’ attention to detail and creative approach to teach me and bring new insights by their comments. Surely, more discussions and introduction of other hemodynamic devices would provide better prevention and management of shock states. Your efforts and dedication in presenting educational materials in this journal are commendable. Best wishes from, Farahnaz Fallahian.
Dear Maria Emerson, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. I am delighted to have published our manuscript, "Acute Colonic Pseudo-Obstruction (ACPO): A rare but serious complication following caesarean section." I want to thank the editorial team, especially Maria Emerson, for their prompt review of the manuscript, quick responses to queries, and overall support. Yours sincerely Dr. Victor Olagundoye.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. Many thanks for publishing this manuscript after I lost confidence the editors were most helpful, more than other journals Best wishes from, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Agrippa Hilda, Editorial Coordinator, Journal of Neuroscience and Neurological Surgery. The entire process including article submission, review, revision, and publication was extremely easy. The journal editor was prompt and helpful, and the reviewers contributed to the quality of the paper. Thank you so much! Eric Nussbaum, MD
Dr Hala Al Shaikh This is to acknowledge that the peer review process for the article ’ A Novel Gnrh1 Gene Mutation in Four Omani Male Siblings, Presentation and Management ’ sent to the International Journal of Clinical Case Reports and Reviews was quick and smooth. The editorial office was prompt with easy communication.
Dear Erin Aust, Editorial Coordinator, Journal of General Medicine and Clinical Practice. We are pleased to share our experience with the “Journal of General Medicine and Clinical Practice”, following the successful publication of our article. The peer review process was thorough and constructive, helping to improve the clarity and quality of the manuscript. We are especially thankful to Ms. Erin Aust, the Editorial Coordinator, for her prompt communication and continuous support throughout the process. Her professionalism ensured a smooth and efficient publication experience. The journal upholds high editorial standards, and we highly recommend it to fellow researchers seeking a credible platform for their work. Best wishes By, Dr. Rakhi Mishra.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. The peer review process of the journal of Clinical Cardiology and Cardiovascular Interventions was excellent and fast, as was the support of the editorial office and the quality of the journal. Kind regards Walter F. Riesen Prof. Dr. Dr. h.c. Walter F. Riesen.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. Thank you for publishing our article, Exploring Clozapine's Efficacy in Managing Aggression: A Multiple Single-Case Study in Forensic Psychiatry in the international journal of clinical case reports and reviews. We found the peer review process very professional and efficient. The comments were constructive, and the whole process was efficient. On behalf of the co-authors, I would like to thank you for publishing this article. With regards, Dr. Jelle R. Lettinga.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, I would like to express my deep admiration for the exceptional professionalism demonstrated by your journal. I am thoroughly impressed by the speed of the editorial process, the substantive and insightful reviews, and the meticulous preparation of the manuscript for publication. Additionally, I greatly appreciate the courteous and immediate responses from your editorial office to all my inquiries. Best Regards, Dariusz Ziora
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation, Auctores Publishing LLC, We would like to thank the editorial team for the smooth and high-quality communication leading up to the publication of our article in the Journal of Neurodegeneration and Neurorehabilitation. The reviewers have extensive knowledge in the field, and their relevant questions helped to add value to our publication. Kind regards, Dr. Ravi Shrivastava.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, Auctores Publishing LLC, USA Office: +1-(302)-520-2644. I would like to express my sincere appreciation for the efficient and professional handling of my case report by the ‘Journal of Clinical Case Reports and Studies’. The peer review process was not only fast but also highly constructive—the reviewers’ comments were clear, relevant, and greatly helped me improve the quality and clarity of my manuscript. I also received excellent support from the editorial office throughout the process. Communication was smooth and timely, and I felt well guided at every stage, from submission to publication. The overall quality and rigor of the journal are truly commendable. I am pleased to have published my work with Journal of Clinical Case Reports and Studies, and I look forward to future opportunities for collaboration. Sincerely, Aline Tollet, UCLouvain.
Dear Ms. Mayra Duenas, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. “The International Journal of Clinical Case Reports and Reviews represented the “ideal house” to share with the research community a first experience with the use of the Simeox device for speech rehabilitation. High scientific reputation and attractive website communication were first determinants for the selection of this Journal, and the following submission process exceeded expectations: fast but highly professional peer review, great support by the editorial office, elegant graphic layout. Exactly what a dynamic research team - also composed by allied professionals - needs!" From, Chiara Beccaluva, PT - Italy.
Dear Maria Emerson, Editorial Coordinator, we have deeply appreciated the professionalism demonstrated by the International Journal of Clinical Case Reports and Reviews. The reviewers have extensive knowledge of our field and have been very efficient and fast in supporting the process. I am really looking forward to further collaboration. Thanks. Best regards, Dr. Claudio Ligresti
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation. “The peer review process was efficient and constructive, and the editorial office provided excellent communication and support throughout. The journal ensures scientific rigor and high editorial standards, while also offering a smooth and timely publication process. We sincerely appreciate the work of the editorial team in facilitating the dissemination of innovative approaches such as the Bonori Method.” Best regards, Dr. Matteo Bonori.
I recommend without hesitation submitting relevant papers on medical decision making to the International Journal of Clinical Case Reports and Reviews. I am very grateful to the editorial staff. Maria Emerson was a pleasure to communicate with. The time from submission to publication was an extremely short 3 weeks. The editorial staff submitted the paper to three reviewers. Two of the reviewers commented positively on the value of publishing the paper. The editorial staff quickly recognized the third reviewer’s comments as an unjust attempt to reject the paper. I revised the paper as recommended by the first two reviewers.
Dear Maria Emerson, Editorial Coordinator, Journal of Clinical Research and Reports. Thank you for publishing our case report: "Clinical Case of Effective Fetal Stem Cells Treatment in a Patient with Autism Spectrum Disorder" within the "Journal of Clinical Research and Reports" being submitted by the team of EmCell doctors from Kyiv, Ukraine. We much appreciate a professional and transparent peer-review process from Auctores. All research Doctors are so grateful to your Editorial Office and Auctores Publishing support! I amiably wish our article publication maintained a top quality of your International Scientific Journal. My best wishes for a prosperity of the Journal of Clinical Research and Reports. Hope our scientific relationship and cooperation will remain long lasting. Thank you very much indeed. Kind regards, Dr. Andriy Sinelnyk Cell Therapy Center EmCell
Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. It was truly a rewarding experience to work with the journal “Clinical Cardiology and Cardiovascular Interventions”. The peer review process was insightful and encouraging, helping us refine our work to a higher standard. The editorial office offered exceptional support with prompt and thoughtful communication. I highly value the journal’s role in promoting scientific advancement and am honored to be part of it. Best regards, Meng-Jou Lee, MD, Department of Anesthesiology, National Taiwan University Hospital.
Dear Editorial Team, Journal-Clinical Cardiology and Cardiovascular Interventions, “Publishing my article with Clinical Cardiology and Cardiovascular Interventions has been a highly positive experience. The peer-review process was rigorous yet supportive, offering valuable feedback that strengthened my work. The editorial team demonstrated exceptional professionalism, prompt communication, and a genuine commitment to maintaining the highest scientific standards. I am very pleased with the publication quality and proud to be associated with such a reputable journal.” Warm regards, Dr. Mahmoud Kamal Moustafa Ahmed
Dear Maria Emerson, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews’, I appreciate the opportunity to publish my article with your journal. The editorial office provided clear communication during the submission and review process, and I found the overall experience professional and constructive. Best regards, Elena Salvatore.
Dear Mayra Duenas, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews Herewith I confirm an optimal peer review process and a great support of the editorial office of the present journal
Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. I am really grateful for the peers review; their feedback gave me the opportunity to reflect on the message and impact of my work and to ameliorate the article. The editors did a great job in addition by encouraging me to continue with the process of publishing.
Dear Cecilia Lilly, Editorial Coordinator, Endocrinology and Disorders, Thank you so much for your quick response regarding reviewing and all process till publishing our manuscript entitled: Prevalence of Pre-Diabetes and its Associated Risk Factors Among Nile College Students, Sudan. Best regards, Dr Mamoun Magzoub.
International Journal of Clinical Case Reports and Reviews is a high quality journal that has a clear and concise submission process. The peer review process was comprehensive and constructive. Support from the editorial office was excellent, since the administrative staff were responsive. The journal provides a fast and timely publication timeline.
Dear Maria Emerson, Editorial Coordinator of International Journal of Clinical Case Reports and Reviews, What distinguishes International Journal of Clinical Case Report and Review is not only the scientific rigor of its publications, but the intellectual climate in which research is evaluated. The submission process is refreshingly free of unnecessary formal barriers and bureaucratic rituals that often complicate academic publishing without adding real value. The peer-review system is demanding yet constructive, guided by genuine scientific dialogue rather than hierarchical or authoritarian attitudes. Reviewers act as collaborators in improving the manuscript, not as gatekeepers imposing arbitrary standards. This journal offers a rare balance: high methodological standards combined with a respectful, transparent, and supportive editorial approach. In an era where publishing can feel more burdensome than research itself, this platform restores the original purpose of peer review — to refine ideas, not to obstruct them Prof. Perlat Kapisyzi, FCCP PULMONOLOGIST AND THORACIC IMAGING.
Dear Grace Pierce, International Journal of Clinical Case Reports and Reviews I appreciate the opportunity to review for Auctore Journal, as the overall editorial process was smooth, transparent and professionally managed. This journal maintains high scientific standards and ensures timely communications with authors, which is truly commendable. I would like to express my special thanks to editor Grace Pierce for his constant guidance, promt responses, and supportive coordination throughout the review process. I am also greatful to Eleanor Bailey from the finance department for her clear communication and efficient handling of all administrative matters. Overall, my experience with Auctore Journal has been highly positive and rewarding. Best regards, Sabita sinha
Dear Mayra Duenas, Editorial Coordinator of the journal IJCCR, I write here a little on my experience as an author submitting to the International Journal of Clinical Case Reports and Reviews (IJCCR). This was my first submission to IJCCR and my manuscript was inherently an outsider’s effort. It attempted to broadly identify and then make some sense of life’s under-appreciated mysteries. I initially had responded to a request for possible submissions. I then contacted IJCCR with a tentative topic for a manuscript. They quickly got back with an approval for the submission, but with a particular requirement that it be medically relevant. I then put together a manuscript and submitted it. After the usual back-and-forth over forms and formality, the manuscript was sent off for reviews. Within 2 weeks I got back 4 reviews which were both helpful and also surprising. Surprising in that the topic was somewhat foreign to medical literature. My subsequent updates in response to the reviewer comments went smoothly and in short order I had a series of proofs to evaluate. All in all, the whole publication process seemed outstanding. It was both helpful in terms of the paper’s content and also in terms of its efficient and friendly communications. Thank you all very much. Sincerely, Ted Christopher, Rochester, NY.
